Biodesix (BDSX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
5 May, 2026Mission and vision
Aims to transform patient care and improve outcomes through timely, accessible, personalized diagnostics addressing immediate clinical needs.
Envisions conquering diseases with the guidance of personalized diagnostics.
Business model and revenue streams
Generates revenue from two business lines: lung diagnostic tests and development services for biopharma, life sciences, and academic partners.
Focuses on supporting clinical decisions in lung disease and enabling partners with scientific and operational capabilities.
Financial performance and growth
FY 2026 revenue guidance increased to $108–114M, representing 25% growth over 2025.
Q1 2026 revenues reached $25.6M, with 42% YoY growth and industry-leading 82% gross margins.
Adjusted EBITDA improved by 35% from Q1 2025.
Latest events from Biodesix
- Sales and clinical momentum support growth, with profitability and pipeline progress in focus.BDSX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% to $26.9M, gross margin at 82%, and net loss improved by 37%.BDSXQ2 2026
- Strong growth, digital expansion, and clinical innovation set the stage for a transformative 2025.BDSX45th Annual William Blair Growth Stock Conference
- Revenue and clinical adoption surge as targeted lung nodule diagnostics drive growth.BDSX46th Annual William Blair Growth Stock Conference
- Registering 375,000 shares for resale by a lender, with proceeds from warrant exercises for working capital.BDSXRegistration filing
- Q1 2026 revenue rose 42% to $25.6M, with improved margins and raised full-year guidance.BDSXQ1 2026
- Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.BDSXProxy filing
- Annual meeting to vote on directors, executive pay, auditor, and governance best practices.BDSXProxy filing
- Q1 2025 revenue up 21%, net loss improved 18%, and 2025 guidance set at $80–85 million.BDSXQ1 2025